Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

571 articles

Research Review

Showing 1–3 of 3 articles · Keyword: lipid nanoparticles (LNPs) Clear keyword

Expert review of clinical pharmacology2026ReviewNon-viral Gene DeliveryDrug Delivery

1. Mathematical modeling in mRNA therapeutics: towards a pathway to individualized treatment protocols

Campanile E, Pettinà E, Marchetti L

mRNA-lipid nanoparticle (mRNA-LNP) therapeutics represent a transformative pharmacological paradigm in which the delivery vehicle, genetic payload, and expressed protein form a tightly coupled system. This multicomponent structure introduces nonlinear, multiscale dynamics that challenge traditional pharmacokinetic…

Read the article

International journal of pharmaceutics2026ResearchDrug Delivery

2. A structure-based virtual screening-driven discovery pharmaceutics platform for cancer therapeutics development: FDA 505(b)(2) repurposing of netupitant as a BMX-targeted nanomedicine using quality-by-design lipid nanoparticles and model-informed PBPK translation

Singirikonda M, Patel T, Parupathi P, Nagarajan A, Patel Js, Devarakonda L, Et Al.

Bone marrow tyrosine kinase on chromosome X (BMX) is an emerging therapeutic target implicated in prostate cancer progression, metastatic disease, and resistance to current therapies; however, no selective BMX-targeted therapy has advanced to clinical development.

Read the article

ACS nanoscience Au2026ResearchNon-viral Gene DeliveryDrug Delivery

3. Lipid Nanoparticles at the Crossroads of Chemistry and Medicine: A Tutorial

Rogado Mt, Wang A, Zeng S, Wang Z, Burda C

Lipid nanoparticles (LNPs) have risen to the forefront of modern therapeutics by enabling the clinical success of COVID-19 mRNA vaccines. In order for them to function as drug delivery vesicles, LNPs must have scalable, tunable, and targeted nanoscale platforms whose strengths in versatility, performance, and…

Read the article

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.